MGB Biopharma, a biopharmaceutical company developing a novel class of anti-infectives to address the major global problem of antibiotic resistance, today announces the completion of its latest unding round. The over-subscribed fund-raise was supported by new and existing investors, led by Archangel Investors and including Scottish Investment Bank (the investment arm of Scottish Enterprise, Scotland’s national economic development agency), Barwell and TriCapital Investors. For the...
MGB Biopharma, a biopharmaceutical company developing a novel class of anti-infectives to address the major global problem of antibiotic resistance, today announces the completion of its latest unding round. The over-subscribed fund-raise was supported by new and existing investors, led by Archangel Investors and including Scottish Investment Bank (the investment arm of Scottish Enterprise, Scotland’s national economic development agency), Barwell and TriCapital Investors. The new funding...
A new drug that could prevent the spread of malaria has been developed after “breakthrough” research. The medicine, delivered by an international team of scientists led by the University of Glasgow, could also be used to treat people suffering with the deadly parasitic disease. For the full article, please see here: https://www.glasgowlive.co.uk/news/glasgow-news/new-malaria-drug-developed-after-16836871
A new drug that could prevent the spread of malaria has been developed after “breakthrough” research. The medicine, delivered by an international team of scientists led by the University of Glasgow, could also be used to treat people suffering with the deadly parasitic disease. For the full article, please see here: https://www.glasgowlive.co.uk/news/glasgow-news/new-malaria-drug-developed-after-16836871
Ivan McKee MSP, Minister of Trade, Investment and Innovation was welcomed on site at BioAscent this week to tour its chemistry, biology and compound management/library facilities. The Minister was interested in finding out more about BioCity Scotland-based BioAscent’s success and the role funding has played in those achievements. He was also keen to find out more about the growing team and the work that is...
AI Design enables new bispecific small molecule modality Exscientia, the world-leading Artificial Intelligence (AI)-driven drug discovery company, today announced that Sanofi has exercised its option to progress an innovative Bispecific Small molecule project it discovered as part of its new modality collaboration. The novel, first-in-class, bispecific investigational small molecule targets two distinct, biologically validated pathways related to inflammation and the progression of fibrosis. Commenting on...